Clinical studies of COVID-19 patient outcomes have proposed that patients with an early and robust IFN response were more likely to have mild-to-moderate disease, while patients with a delayed or blunted response were more likely to succumb to severe COVID (52, 53). The gene discussed is IFNA1; the disease is COVID-19.